

In particular, applicants emphasize that the rejection fails to establish any motivation for combining with an AII antagonist a compound having the activity of lowering postprandial hyperglycemia in diabetes mellitus (see claim 33).

Accordingly, withdrawal of the rejection under 35 U.S.C. 103 is requested.

In accordance with the foregoing, favorable reconsideration and allowance of the application are requested. In the event that any issues remain, the Examiner is invited to telephone the undersigned with any proposal to expedite prosecution.

Respectfully submitted,

Date: January 23, 2002

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5569
Facsimile: (202) 672-5399

By Phillip J. Artwols *Reg. No.*
for / Stephen B. Maebius *38,819*
Attorney for Applicants
Registration No. 35,264

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No. 19-0741 for any such fees; and applicant(s) hereby petition for any needed extension of time.